🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesBlood pressure went from scary to perfect - anyone else?

Blood pressure went from scary to perfect - anyone else?

steve_okc Sat, May 9, 2026 at 1:10 AM 19 replies 803 viewsPage 1 of 4
steve_okc
Member
489
2,123
Jul 2024
Oklahoma City, OK
May 9, 2026 at 1:10 AM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

The question I want answered is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

I have searched first, so if this is covered somewhere point me at it and I will read it.

30 0NauseaFreeNow, SteveThurs, B12Beth and 27 others
Reply Quote Save Share Report
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
May 9, 2026 at 1:34 AM#2
steve_okc said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

6 month update on cardiovascular risk: down 42 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

Last edited: May 9, 2026 at 3:34 AM
29 24wei_SG, cory_ATX, lori_vegas and 26 others
Reply Quote Save Share Report
tom_AK
New Member
28
112
Jan 2026
Anchorage, AK
May 9, 2026 at 1:58 AM#3
Dr.LipidDallas said:
6 month update on cardiovascular risk: down 42 lbs, off blood pressure meds, A1C normalized.

I want to bring up the cardiovascular angle on cardiovascular risk.

The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.

For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.

References:
[1] Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.
28 23tyler_CSCS, VanRx_Mike, steve_okc and 25 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
RegAffairsDC
Member
678
3,456
May 2024
Washington, DC
May 9, 2026 at 2:21 AM#4
steve_okc said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

This matches mine closely enough to be worth saying so out loud.

Last edited: May 9, 2026 at 4:21 AM
27 22sean_dublin, hannah_MT, Dr.SportsMedIN and 24 others
Reply Quote Save Share Report
sophie_paris
Member
212
890
Nov 2024
Paris, FR
May 9, 2026 at 4:29 AM#5

Adding the clinical framing, because it changes how the question reads.

I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

16 months later: down 43 lbs, off atorvastatin, A1C from 8.6% to 5.2%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

26 21BethLabQueen, ChrisMacros, KetoKyle and 23 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register